The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.

ABSTRACT: Antibody-drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing damage to healthy cells and reducing systemic toxicity. Their design allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently among the most promising drug classes in oncology, with efforts to expand their application for nononcological indications and in combination therapies. Here we provide a detailed overview of the recent advances in ADC research and consider future directions and challenges in promoting this promising platform to widespread therapeutic use. We examine data from the CAS Content Collection, the largest human-curated collection of publis

SUBMITTER: Sasso JM 

PROVIDER: S-EPMC10655051 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature